Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Probiotical S P A maintains a patent portfolio in the Biotechnology & Pharmaceuticals technology area with 2 pending office actions currently active. These actions are distributed across 2 distinct examiners, showing that the company is navigating multiple simultaneous reviews. The presence of 2 distinct art units suggests that the underlying technologies span different specialized classifications within the broader biotech sector, requiring a varied approach to prosecution.
Among the active matters, the busiest examiner is DICKENS, AMELIA NICOLE, who accounts for 1 busiest examiner pending office action. This distribution means that the total of 2 pending office actions is shared between the 2 distinct examiners. For the practitioner, this indicates a prosecution profile where the success of the portfolio is not dependent on a single individual. The parity between the number of examiners and art units implies that each examiner is likely operating within a different technical framework, necessitating tailored arguments for each specific case.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DICKENS, AMELIA NICOLE | 1 | 47.6% | +21.1% |
| CRUM, MARY ABOU NADER | 1 | 40.4% | +65.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17917458 | USE OF BACTERIAL STRAINS LACTOBACILLUS BREVIS, LACTOBACILLUS PLANTARUM AND/OR LACTOBACILLUS PENTOSUS IN THE REDUCTION OF AN INGESTED OR ACCUMULATED AMOUNT OF PHOSPHONATES IN THE HUMAN MICROBIOTA | CRUM, MARY ABOU NADER | 8d overdue |
| 18560643 | STRAINS OF PROBIOTIC BACTERIA FOR USE IN A PREVENTIVE METHOD OF TREATMENT OR IN AN ADJUVANT METHOD OF TREATMENT OF VIRAL RESPIRATORY INFECTIONS | DICKENS, AMELIA NICOLE | — |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| 1657 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18560643 | STRAINS OF PROBIOTIC BACTERIA FOR USE IN A PREVENTIVE METHOD OF TREATMENT OR IN AN ADJUVANT METHOD OF TREATMENT OF VIRAL RESPIRATORY INFECTIONS | DICKENS, AMELIA NICOLE | 1645 | §112 | Non-Final OA | — | Pending | Nov 13, 2023 |
| 17917458 | USE OF BACTERIAL STRAINS LACTOBACILLUS BREVIS, LACTOBACILLUS PLANTARUM AND/OR LACTOBACILLUS PENTOSUS IN THE REDUCTION OF AN INGESTED OR ACCUMULATED AMOUNT OF PHOSPHONATES IN THE HUMAN MICROBIOTA | CRUM, MARY ABOU NADER | 1657 | §112 | Final Rejection | 8d overdue | Pending | Oct 06, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial